{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-004497","form_type":"8-K/A","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2022-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.031855+00:00","generated_at":"2026-06-27T17:56:57.215024+00:00","sec_items":["9.01","5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VYNE director Rex Bright dies; board appoints LePore, Sandoval; MST sale yields $20M upfront","bullets":["Director Rex Bright passed away on Jan 11, 2022; he chaired Compensation Committee and served on Audit Committee.","Board appointed Patrick LePore to Audit Committee and Elisabeth Sandoval as chair of Compensation Committee on Jan 14, 2022.","MST franchise sold to Journey Medical for $20M upfront, $5M in 1 year, plus up to $450M in milestone payments.","Pro forma balance sheet shows cash of $67.9M after sale; discontinued operations eliminate product sales revenues.","Pro forma net loss from continuing ops for nine months ended Sep 30, 2021 was $37.1M, down from $61.8M historical."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-004497","json":"https://secwatch.observer/filing/0001104659-22-004497.json","markdown":"https://secwatch.observer/filing/0001104659-22-004497.md","text":"https://secwatch.observer/filing/0001104659-22-004497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922004497/0001104659-22-004497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922004497/tm222963d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T17:56:57.215024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8ca5f4fd3","claim":"Rex Bright departed as Director at VYNE Therapeutics Inc..","evidence_excerpt":"The Company deeply regrets to announce that Mr. Rex Bright passed away on January 11, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465922004497/0001104659-22-004497-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"passed away"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}